MAPT and Alzheimer disease: Despite low BBB permeability, RSG demonstrates therapeutic potential in pre-clinical models of AD via the enhancement of multiple signaling mechanisms, improvement in cognitive and synaptic function, reduction of neuroinflammation, and modulation of key signaling proteins involved in the pathogenesis of AD, such as GSK3β, tau, and Aβ.